Corcept Therapeutics' President, Sean Maduck, was involved in several transactions concerning shares of CORCEPT THERAPEUTICS INC (NASDAQ:CORT) on June 1 and June 2, 2026. Mr. Maduck sold a total of 25,000 shares of common stock, achieving a combined value of $1,755,183. Concurrently with these sales, he also exercised options to acquire an additional 25,000 shares.
The stock was trading at $72.68 at the time of the transactions, which represented an increase from $71.20 on the day of the activity. This pricing reflects a significant year-to-date gain of 109%. The sales that took place on June 1 were executed across a price range spanning from $69.49 to $70.95 per share. Notably, these transactions were managed through a Rule 10b5-1 trading plan, which Mr. Maduck had initially implemented on December 8, 2025.
Detailed Transaction Breakdown
On June 1, alongside the sale of common stock, Mr. Maduck also exercised stock options to acquire 25,000 shares of Corcept Therapeutics common stock. The exercise price for these options was set at $8.27 per share, resulting in a total cost of $206,750. These specific options were fully exercisable.
In related acquisitions, Mr. Maduck further acquired 615 shares of common stock through a company purchase plan, purchasing them at $70.44 per share. Additionally, he obtained another 615 shares classified as unvested restricted stock awards via the same purchase plan. These restricted shares are contingent upon specific conditions and are scheduled to vest on the one-year anniversary of their grant date.
The activity continued on June 2, 2026, when the company withheld 452 shares at a price of $70.44 per share. This withholding action was specifically intended to cover tax obligations associated with the vesting of restricted stock units.
Current Holdings and Market Valuation
Following these recent transactions, Mr. Maduck currently maintains direct ownership of 9,755 shares of Corcept Therapeutics common stock. His holdings also include various indirect interests across multiple entities:
- Sean and Molly Maduck Living Trust: 5,147 shares
- MMM 2025, LLC: 20,570 shares
- SNM 2025 Grantor Retained Annuity Trust: 40,000 shares
- SNM 2026 Grantor Retained Annuity Trust: 34,000 shares
- Duckhill Capital, LLC: 10,000 shares (Beneficial ownership is disclaimed by Mr. Maduck, except for his pecuniary interest).
From a market perspective, according to InvestingPro analysis, the stock is currently slightly overvalued relative to its Fair Value, exhibiting a high Price-to-Earnings (P/E) ratio of 180. The platform also provides insight into CORT investors, including 13 ProTips and indicating that the company has a